At the same time, ERβ is an important target for the treatment of prostate cancer, and its expression level is different in normal prostate tissue, prostatic hyperplasia tissue, benign prostate cancer tissue, and high-grade prostate cancer tissue [10,11]. Here, ESR2 is linked to prostate carcinoma.